Exosomal <scp>microRNA</scp>‐15a from <scp>ACHN</scp> cells aggravates clear cell renal cell carcinoma via the <scp>BTG2</scp>/<scp>PI3K</scp>/<scp>AKT</scp> axis

Li, Daoyuan; Lin, Feifei; Li, Guoping; Zeng, Fanchang

doi:10.1002/kjm2.12428

Cited by 15 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the presence of exosomal miR-15a has been shown to enhance the activity of EMT in clear cell RCC. This effect is achieved through the downregulation of the BTG2 gene and promotion of the PI3K/AKT signaling pathway [ 123 ]. Furthermore, Hu and colleagues discovered that exosomal lncHILAR is associated with gene bank markers associated with EMT, as indicated by gene enrichment analysis.…”

Section: The Contribution Of Exosomes To Rccmentioning

confidence: 99%

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer

Boussios,

Devo,

Goodall

et al. 2023

IJMS

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases. The primary treatment modalities for RCC are surgery and targeted therapy, albeit with suboptimal efficacies. Despite progress in RCC research, significant challenges persist, including advanced distant metastasis, delayed diagnosis, and drug resistance. Growing evidence suggests that extracellular vesicles (EVs) play a pivotal role in multiple aspects of RCC, including tumorigenesis, metastasis, immune evasion, and drug response. These membrane-bound vesicles are released into the extracellular environment by nearly all cell types and are capable of transferring various bioactive molecules, including RNA, DNA, proteins, and lipids, aiding intercellular communication. The molecular cargo carried by EVs renders them an attractive resource for biomarker identification, while their multifarious role in the RCC offers opportunities for diagnosis and targeted interventions, including EV-based therapies. As the most versatile type of EVs, exosomes have attracted much attention as nanocarriers of biologicals, with multi-range signaling effects. Despite the growing interest in exosomes, there is currently no widely accepted consensus on their subtypes and properties. The emerging heterogeneity of exosomes presents both methodological challenges and exciting opportunities for diagnostic and clinical interventions. This article reviews the characteristics and functions of exosomes, with a particular reference to the recent advances in their application to the diagnosis and treatment of RCC.

show abstract

Section: The Contribution Of Exosomes To Rccmentioning

confidence: 99%

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer

Boussios,

Devo,

Goodall

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…For instance, Li et al. ( 45 ) discovered that sEVs generated by RCC cells can regulate the activity of RCC cells via miR-15a. B-cell translocation gene 2 (BTG2), a miR-15a downstream gene, had a negative connection with miR-15a expression.…”

Section: Evs In Rcc Deteriorationmentioning

confidence: 99%

Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist

Zhang

Zhou

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) represents an extremely challenging disease in terms of both diagnosis and treatment. It poses a significant threat to human health, with incidence rates increasing at a yearly rate of roughly 2%. Extracellular vesicles (EVs) are lipid-based bilayer structures of membranes that are essential for intercellular interaction and have been linked to the advancement of RCC. This review provides an overview of recent studies on the role of EVs in RCC progression, including involvement in the interaction of tumor cells with M2 macrophages, mediating the generation of immune tolerance, and assuming the role of communication messengers in the tumor microenvironment leading to disease progression. Finally, the “ troika “ of EVs in RCC therapy is presented, including engineered sEVs’ or EVs tumor vaccines, mesenchymal stem cell EVs therapy, and reduction of tumor-derived EVs secretion. In this context, we highlight the limitations and challenges of EV-based research and the prospects for future developments in this field. Overall, this review provides a comprehensive summary of the role of EVs in RCC and their potential as a viable pathway for the future treatment of this complex disease.

show abstract

“…The used sequence-specific primers for miRNA 15a are shown in Table 1. 16 The components of qRT-PCR mixture, as shown in Table 2, were prepared in polypropylene tubes. The PCR tubes were placed and processed in a thermal cycler (Step One thermal cycler with software version 3.1, Applied Biosystems, USA) for amplification and analysis.…”

Section: -Reverse Transcriptionmentioning

confidence: 99%

Serum level of MicroRNA 15a and interleukin 6 as biomarkers for sepsis in critically Ill Patients

Nader

Abdelmaseeh

Sharif

et al. 2023

EJI

View full text Add to dashboard Cite

This study intended to evaluate the diagnostic efficacy of serum interleukin-6 (IL-6) and serum expression level of microRNA 15a (miRNA 15a) in sepsis patients admitted to the medical intensive care unit (ICU), and to correlate the results with the outcome of patients. This observational case-control study, was done from January 2022 to June 2022, included 75 adult ICU patients ≥18 years old, divided into 2 groups. Group 1: included 38 adults, critically ill sepsis patients and Group 2 (control group), included 37 adults, non-sepsis patients admitted to the ICU. Venous blood was withdrawn from cases and controls under aseptic conditions for assessment of serum IL-6 level by ELISA and serum expression level of miRNA 15a by quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR). Patient demographic data in addition to their characteristics including site of infection, blood culture results, length of stay and outcome of patients were included in the study. miRNA 15a was significantly higher in the sepsis group with mean of 3.99±1.61 compared to the controls (1.03±0.03, p< 0.001) while serum IL-6 levels were higher in the sepsis patients compared to the controls, however the difference did not reach statistical significance (p= 0.92). No difference was found in IL-6 and miRNA 15a levels between surviving and non-surviving sepsis patients, shocked and non-shocked sepsis patients. In conclusion, both IL-6 and miRNA 15a were up-regulated in ICU patients with sepsis. Both biomarkers did not show a significant difference regarding the outcome of patients. miRNA 15a could be considered a highly speciﬁc and sensitive marker in differentiating sepsis cases from controls, so it could be used as a diagnostic rather than a prognostic biomarker for sepsis.

show abstract

Exosomal microRNA‐15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis

Cited by 15 publications

References 36 publications

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer

Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist

Serum level of MicroRNA 15a and interleukin 6 as biomarkers for sepsis in critically Ill Patients

Contact Info

Product

Resources

About